A groundbreaking study from UCLA Health has unveiled a sex chromosome–linked gene that exacerbates inflammation in the female brain, shedding new light on the underlying causes for women’s increased vulnerability to neurological disorders like Alzheimer’s disease and multiple sclerosis. This research not only advances our understanding of sex-based differences in neurological disease susceptibility but also points toward promising therapeutic strategies targeting this genetic factor.
Published in the esteemed journal Science Translational Medicine, this study leverages sophisticated mouse models of multiple sclerosis to probe the genetic underpinnings of brain inflammation. The team pinpointed a gene located on the X chromosome, named Kdm6a, that plays a decisive role in activating microglia—the brain’s resident immune cells responsible for inflammatory responses. Because females inherit two X chromosomes, they effectively receive a double dose of this inflammation-driving gene’s activity, which may predispose them to more severe chronic neuroinflammatory conditions.
Microglial activation is a critical contributor to neurodegenerative processes observed in aging, Alzheimer’s disease, and multiple sclerosis, intensifying the urgency to decipher mechanisms operating distinctly in female brains. The UCLA researchers employed a gene knockout approach to specifically deactivate Kdm6a within microglia, resulting in a remarkable attenuation of MS-like disease symptoms and neuropathological markers in female mice. This compelling evidence confirms Kdm6a as a pivotal regulator of inflammatory pathways in sex-specific neuroimmune responses.
Dr. Rhonda Voskuhl, the study’s lead author and director of UCLA’s Multiple Sclerosis Program, emphasized the clinical relevance by noting that neurological diseases such as multiple sclerosis and Alzheimer’s disproportionately affect women at rates two to three times higher than men. She also highlighted the prevalence of “brain fog” during menopause, linking it to underlying inflammatory shifts modulated by sex chromosomes and hormones. The discovery of Kdm6a’s role offers a genetic explanation contributing to these sex-based disparities.
Further mechanistic insights were gained through pharmacological experiments where the protein expressed by Kdm6a was downregulated via the widely prescribed drug metformin. Traditionally used to treat type 2 diabetes, metformin is increasingly being investigated for its anti-aging and inflammation-modulating properties. Intriguingly, the treatment produced significant amelioration of inflammatory markers in female mice, but minimal effects in males, reinforcing the sex-specific influence of this X-chromosomal gene.
The sex difference in response is explicable by the gene dosage effect: females possess two active copies of Kdm6a compared to males’ single copy, creating a higher baseline of gene-associated inflammation. This biological nuance provides a compelling rationale for the observed epidemiological patterns of sex bias in neurological diseases and suggests that therapeutic interventions might need to be sex-tailored for maximum efficacy.
Beyond genetic dosage, the hormone milieu significantly modulates the gene’s proinflammatory activity. Estrogen, which is prevalent during reproductive years, serves as a neuroprotective and anti-inflammatory agent that counterbalances Kdm6a-driven inflammation. As women age and undergo menopause, estrogen levels decline precipitously, removing this inhibitory influence and allowing inflammation to surge, which could exacerbate neurodegenerative trajectories and cognitive symptoms like brain fog.
This hormone-genome interaction underscores an evolutionary balance where female brains leverage heightened X-linked immune responses to protect against infections during gestational and reproductive periods, but at the cost of increased inflammatory risk with advancing age. The study posits that restoring estrogenic signaling or directly targeting Kdm6a function could recalibrate this imbalance and serve as viable therapeutic avenues.
The implications of this research extend far beyond multiple sclerosis, potentially reshaping our understanding of Alzheimer’s disease pathogenesis and other female-prevalent neurodegenerative disorders. By elucidating a concrete genetic and molecular pathway that potentiates neuroinflammation specifically in females, it lays the groundwork for precision medicine approaches tailored by sex, genetic background, and hormonal status.
While the findings primarily emerge from animal models, the translational potential is significant. Future clinical studies examining metformin’s efficacy in women with neurodegenerative diseases, stratified by hormonal status, could pioneer new treatment modalities that harness this sex-specific vulnerability. Moreover, interventions aiming to modulate Kdm6a or its downstream effectors could provide critical neuroprotection during the menopausal transition, preserving cognitive function and quality of life.
Dr. Voskuhl and colleagues envision a future where neurological health in women is managed through integrative strategies that combine genomic insights with hormonal therapies. Such an approach stands to mitigate neuroinflammatory burdens and reduce the incidence and severity of devastating diseases for which women are disproportionately at risk.
In conclusion, the identification of Kdm6a as a driver of female-specific brain inflammation revolutionizes the field of neuroimmunology. This discovery not only explains longstanding clinical observations of sex disparities in brain disorders but also opens new horizons for personalized therapies that could profoundly improve outcomes for millions of women worldwide.
Subject of Research: Animals
Article Title: Microglia-specific deletion of the X-chromosomal gene Kdm6a reverses the disease-associated microglia translatome in female mice
News Publication Date: 15-Oct-2025
Web References: N/A
References: N/A
Image Credits: N/A
Keywords: Alzheimer disease, Neurodegenerative diseases, Multiple sclerosis, Neurological disorders, Sex chromosomes, X chromosomes, Inflammation, Inflammatory response
